The drug appears to reduce the pace of the disease, in early data from clinical trials.
Trial results of a drug appearing to slow Alzheimer's disease represent a "historic moment", experts say.works when given in the early stages of the disease.And even the limited data has generated excitement among dementia scientists and charities.The drug, lecanemab, is designed to remove clumps of toxic beta-amyloid proteins that build up in the brains of people with Alzheimer's disease.
In this trial, 1,795 volunteers in the early stages of Alzheimer's disease were injected with lecanemab every two weeks and regularly had their memory and mental agility tested. The companies are now applying for regulatory approval for the drug to be given in the US, Europe and Japan. Prof John Hardy, from University College London, said the results were "truly encouraging" and "look like the first truly positive mechanistic trial results in Alzheimer's disease"."This is clearly not a magic bullet but it looks like a definite 'end of the beginning'."But its US launch was widely criticised and the EU refused to allow it over doubts about whether it worked.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Alzheimer’s Drug Slows Disease Progression in TrialEisai and Biogen said their experimental Alzheimer’s drug significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects of approval.
続きを読む »
Alzheimer's drug slowed progression of the disease in Phase 3 trialThe Japanese drugmaker Eisai said Tuesday its experimental drug for Alzheimer’s disease helped slow cognitive decline in patients in the early stages of the illness.
続きを読む »
Alzheimer’s Drug Slowed Rate of Decline: New StudyThe drug reduced cognitive decline by 27 percent in people who received the drug compared to a placebo, the study found.
続きを読む »
Alzheimer's drug slows progression of cognitive decline in clinical trial, drugmakers say | CNNA monoclonal antibody treatment for Alzheimer's disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday.
続きを読む »
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug successBiogen and partner Eisai late Tuesday reported positive results from a late stage, large trial of their experimental Alzheimer's drug.
続きを読む »
Nutrition labels on the front of packages? Biden administration pushes for next stepsThe Food and Drug Administration will research and propose developing a standardized, front-of-package food labeling system to help consumers make healthier choices, the White House said.
続きを読む »